Works by Long, Yujun
Results: 14
Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.
- Published in:
- Translational Psychiatry, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41398-024-02800-7
- By:
- Publication type:
- Article
Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.
- Published in:
- Translational Psychiatry, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41398-024-02800-7
- By:
- Publication type:
- Article
Controlled‐release alginate‐bentonite polymer gel granules of emamectin benzoate and control efficacy against Spodoptera frugiperda.
- Published in:
- Pest Management Science, 2023, v. 79, n. 1, p. 324, doi. 10.1002/ps.7202
- By:
- Publication type:
- Article
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
- Published in:
- Psychopharmacology, 2022, v. 239, n. 1, p. 83, doi. 10.1007/s00213-021-06042-z
- By:
- Publication type:
- Article
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.
- Published in:
- Psychopharmacology, 2021, v. 238, n. 9, p. 2449, doi. 10.1007/s00213-021-05866-z
- By:
- Publication type:
- Article
The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial.
- Published in:
- Translational Psychiatry, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41398-022-01958-2
- By:
- Publication type:
- Article
Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial.
- Published in:
- Frontiers in Psychiatry, 2021, v. 11, p. N.PAG, doi. 10.3389/fpsyt.2021.611070
- By:
- Publication type:
- Article
Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials.
- Published in:
- Frontiers in Psychiatry, 2018, p. N.PAG, doi. 10.3389/fpsyt.2018.00620
- By:
- Publication type:
- Article
The Effect of Accelerated Continuous Theta Burst Stimulation on Weight Loss in Overweight Individuals With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.
- Published in:
- Schizophrenia Bulletin, 2024, v. 50, n. 3, p. 589, doi. 10.1093/schbul/sbad144
- By:
- Publication type:
- Article
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.
- Published in:
- Schizophrenia Bulletin, 2022, v. 48, n. 4, p. 850, doi. 10.1093/schbul/sbac044
- By:
- Publication type:
- Article
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.
- Published in:
- BMC Psychiatry, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12888-022-03853-y
- By:
- Publication type:
- Article
Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial.
- Published in:
- Lipids in Health & Disease, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12944-024-02214-w
- By:
- Publication type:
- Article
Subgroups of cognitive impairments in schizophrenia characterized by executive function and their morphological features: a latent profile analysis study.
- Published in:
- BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-024-03835-9
- By:
- Publication type:
- Article
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02968-7
- By:
- Publication type:
- Article